Mira Pharmaceuticals, INC 8-K filings
NASDAQ
MIRA Pharmaceuticals has amended its employment agreement with CEO Erez Aminov, increasing his base salary and enhancing severance benefits under certain termination scenarios.
NASDAQ
Mira Pharmaceuticals has announced a significant restructuring of its board of directors and changes in key personnel, including the appointment of new board members and a new Chief Scientific Advisor.
NASDAQ
8-K: Mira Pharmaceuticals Discovers New Molecule, MIRA-55, with Enhanced Potency Over Original Candidate
Mira Pharmaceuticals has discovered that a compound used in previous pre-clinical studies, initially believed to be MIRA1a, is actually a new molecule called MIRA-55, which shows enhanced potency and potential for efficacy.
NASDAQ
Christos Nicholoudis, Esq. has resigned from the Board of Directors and as part-time General Counsel of Mira Pharmaceuticals, effective January 15, 2024.